Key facts
- MedaSystems’s last known valuation is $17.5M (Mar 2025).
- It has raised $7.0M; the latest was Seed Round ($2.5M) in Mar 2025.
- Notable investors include Debiopharm Innovation Fund, Nina Capital, Young Sohn.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for MedaSystems
- ·The full record, as it builds
Funding rounds
No funding rounds for MedaSystems are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About MedaSystems
Developer of a cloud-based platform designed to streamline the handling of requests for experimental therapies. The company's platform includes configurable workflows, a form builder that allows the capture of complex, structured, therapy-specific data, task management and tracking, and integration with machine learning libraries, offering to collaborate with physicians around requests for investigational medicines, trial requests, and post-trial access, enabling physicians to organize workflow and streamline requests.
- Sector
- Healthcare
- HQ
- Menlo Park, CA, United States
- Founded
- 2020
- Employees
- 10
- Website
- medasystems.com/
- Ownership
- Privately Held (backing)
MedaSystems doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in MedaSystems shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on MedaSystems in its N-PORT filings yet. We sweep new filings monthly.